Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
about
Erythropoiesis-stimulating agents for anaemia in chronic kidney disease: Are they all the same?Biosimilars: How Can Payers Get Long-Term Savings?An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.Key drivers for market penetration of biosimilars in Europe.Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?Emerging drugs for the treatment of kidney disease-induced anemia.Drug tendering: drug supply and shortage implications for the uptake of biosimilarsEfficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis.Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.
P2860
Q24187090-F993481F-75E8-4CE1-8BF0-955CB3FD461BQ28834400-620B21F4-98D4-4E03-B966-49E1D2AE28B7Q35762997-256C32D4-E449-47CB-9D10-842E5C480188Q37669625-27F8F24D-C7C1-4E97-884D-A4FC20F44915Q38893192-0D2367E2-6874-4774-9183-58A5D7F1FF30Q38930912-C40485B6-2D3E-4DF2-84B0-2207EA4BE963Q42370596-E0626F4B-32BD-4B35-8145-47B111BE9956Q48088431-865071E0-AFB1-4FC2-9914-414F30780E1EQ50483003-2A31A391-FBF4-4ACE-A674-98F462BC922AQ51022840-70BF5F61-1CBE-4071-AF00-06319A74A19C
P2860
Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Biosimilar versus patented ery ...... opean and Japanese experience.
@en
Biosimilar versus patented ery ...... opean and Japanese experience.
@nl
type
label
Biosimilar versus patented ery ...... opean and Japanese experience.
@en
Biosimilar versus patented ery ...... opean and Japanese experience.
@nl
prefLabel
Biosimilar versus patented ery ...... opean and Japanese experience.
@en
Biosimilar versus patented ery ...... opean and Japanese experience.
@nl
P2093
P2860
P1476
Biosimilar versus patented ery ...... opean and Japanese experience.
@en
P2093
Anne-Laure Cordonnier
Claude Le Pen
François Bocquet
Isabelle Fusier
Martine Sinègre
Pascal Paubel
P2860
P2888
P356
10.1007/S40258-014-0125-6
P577
2015-02-01T00:00:00Z